LY2127399 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsing-Remitting Multiple Sclerosis

Conditions

Relapsing-Remitting Multiple Sclerosis

Trial Timeline

Apr 1, 2009 → Jun 1, 2012

NCT ID

NCT00882999

About LY2127399 + Placebo

LY2127399 + Placebo is a phase 2 stage product being developed by Eli Lilly for Relapsing-Remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00882999. Target conditions include Relapsing-Remitting Multiple Sclerosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01488708	Phase 3	Terminated	Jan 1, 2012	Oct 1, 2015	Systemic Lupus Erythematosus
NCT01202760	Phase 3	Completed	Jan 1, 2011	Jul 1, 2013	Rheumatoid Arthritis
NCT00882999	Phase 2	Completed	Apr 1, 2009	Jun 1, 2012	Relapsing-Remitting Multiple Sclerosis
NCT00785928	Phase 2	Completed	Oct 1, 2008	Dec 1, 2010	Rheumatoid Arthritis
NCT00689728	Phase 2	Completed	Jun 1, 2008	May 1, 2010	Arthritis, Rheumatoid
NCT00308282	Phase 2	Completed	Mar 28, 2006	Oct 18, 2007	Arthritis, Rheumatoid

Competing Products

20 competing products in Relapsing-Remitting Multiple Sclerosis

See all competitors

Product	Company	Stage	Hype Score
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
Daclizumab	AbbVie	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccine	AbbVie	Phase 2	52
BIIB019 (Daclizumab)	AbbVie	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo	AbbVie	Phase 3	77
Rebif (Interferon beta-1a)	Merck	Pre-clinical	23
Interferon beta-1a	Merck	Pre-clinical	23
Rebif® + Avonex®	Merck	Phase 3	77
Rebif® + Rebif®	Merck	Approved	85
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone	Merck	Phase 2	52
Placebo + IFN beta-1a + Methylprednisolone	Merck	Phase 2	52
Interferon beta-1a (Rebif)	Merck	Approved	85
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched Placebo	Merck	Phase 3	77
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched Placebo	Merck	Phase 3	77
Interferon beta 1a	Merck	Pre-clinical	23
Cladribine 10 mg oral tablet	Merck	Approved	85
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + Tecfidera	Merck	Phase 2	52
Minocycline + Placebo	Merck	Phase 2	52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved